Provided herein are methods of preventing and treating polybacterial infections comprising administering an effective amount of an antibody or antigen-binding fragment thereof that specifically binds to an epitope produced by at least one of the bacterium in the polybacterial infection. For example, an antibody that specifically binds to Staphylococcus aureus alpha toxin can be administered to a patient with a polybacterial infection comprising Staphylococcus aureus and Pseudomonas aeruginosa to inhibit the growth of Pseudomonas aeruginosa.

Antibody molecule-drug conjugates (ADCs) that specifically bind to lipopolysaccharides (LPS) are disclosed. The antibody molecule-drug conjugates can be used to treat, prevent, and/or diagnose bacterial infections and related disorders.

The present disclosure provides antibodies and antigen-binding fragments of antibodies that bind to Pseudomonas aeruginosa PcrV, and methods of using the same. According to certain embodiments, the disclosure includes antibodies and antigen-binding fragments of antibodies that bind PcrV. The anti-PcrV antibodies and antigen-binding fragments are useful for the prevention and treatment of P. aeruginosa infections.

The present disclosure provides antibodies and antigen-binding fragments of antibodies that bind to Pseudomonas aeruginosa PcrV, and methods of using the same. According to certain embodiments, the disclosure includes antibodies and antigen-binding fragments of antibodies that bind PcrV. The anti-PcrV antibodies and antigen-binding fragments are useful for the prevention and treatment of P. aeruginosa infections.

Provided are antibodies including antigen-binding fragment thereof that specifically recognizing Pseudomonas PcrV. Also provided are methods of making and using these antibodies.

Disclosed herein are compositions for generating a synthetic antibody or synthetic multivalent antibody in a subject. Also disclosed are methods for generating a synthetic antibody or synthetic multivalent antibody in a subject by administering a composition including a recombinant nucleic acid sequence that encodes an antibody, a synthetic antibody, or a synthetic multivalent antibody to a subject. The disclosure also provides compositions and methods of preventing and/or treating a bacterial infection in a subject using said antibody, synthetic antibody, or synthetic multivalent antibody.

Binding agents able to disrupt bacterial biofilms of diverse origin are described, including monoclonal antibodies secreted by human B lymphocytes. Methods to prevent formation of or to dissolve biofilms with these binding agents are also described. Immunogens for eliciting antibodies to disrupt biofilms are also described.

Non-naturally occurring vesicles derived from bacteria, e.g., pathogenic bacteria, methods for making the vesicles, and methods for using compositions of these vesicles are disclosed. Methods of using the vesicles include prevention and/or treatment of bacterial infections. Also provided herein are compositions that include vesicles derived front bacteria and tumor vesicles, methods for making the tumor vesicles, and methods for using the compositions of bacterial vesicles and tumor vesicles. Methods of using the compositions of bacterial vesicles and tumor vesicles include treatment of cancer in a subject. Tumor vesicles may be derived from cancer cells present in the subject to be treated or from a cancer cell line expressing at least one neoantigen. The neoantigen may be specific to the subject and may have been identified by sequencing of the cancer cells from the subject. The neoantigen may be a neoantigen known to be commonly expressed in a particular type of cancer.

Disclosed are immunogenic proteins from Pseudomonas aeruginosa as well as nucleic acids, vectors and transformed cells useful for expression of the proteins. Also disclosed are methods for prophylaxis of infection with Pseudomonas aeruginosa using the proteins, nucleic acids, vectors or transformed cells.

Antibody molecule-drug conjugates (ADCs) that specifically bind to lipopolysaccharides (LPS) are disclosed. The antibody molecule-drug conjugates can be used to treat, prevent, and/or diagnose bacterial infections and related disorders.